APGE — Apogee Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1974640 ·
Last close
$86.19
Market Cap
$5.34B
52W High
$95.32
52W Low
$65.22
ADV30
926,360
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -82,772,000 | -74,111,000 | 1,293,654,000 | 451,797,000 | 37,861,000 |
| Dec 2025 | 0 | — | -78,056,000 | -69,387,000 | 937,134,000 | 131,549,000 | 33,251,000 |
| Sep 2025 | 0 | — | -71,278,000 | -65,021,000 | 626,159,000 | 107,914,000 | 39,821,000 |
| Jun 2025 | 0 | — | -73,165,000 | -66,096,000 | 657,772,000 | 124,192,000 | 38,371,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-234,543,000
Investing CF
$-227,905,000
Financing CF
$807,035,000
CapEx
$-5,898,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.18
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-635,870,000
Inventory
—
Receivables
$7,281,000
ST Investments
$608,088,000
EBIT TTM
$-305,271,000
Pretax Income TTM
$-274,341,000
Interest Exp TTM
—
Analysts
17
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -285,595,000 | -255,843,000 | 937,134,000 | 33,251,000 | — | -227,450,000 |
| Dec 2024 | 0 | -216,870,000 | -182,146,000 | 753,951,000 | 37,157,000 | — | -171,174,000 |
| Dec 2023 | 0 | -93,003,000 | -83,985,000 | 401,404,000 | 21,491,000 | — | -74,761,000 |
| Dec 2022 | 0 | -30,727,000 | -39,785,000 | 152,055,000 | 9,980,000 | — | -16,427,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.19
Max Pain — expiry 2026-07-17
max pain strike: $80.00 · spot: $85.24 · call oi: 1,465 · put oi: 3,734
Expected Move to 2026-07-17:
±$9.73
(11.41%) —
implied range
$75.51 –
$94.96
· ATM straddle on $85.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | $5.25B | $59.55 | — |
| CRSP | CRISPR Therapeutics AG | $5.18B | $52.61 | — |
| SRRK | Scholar Rock Holding Corp | $5.50B | $45.92 | — |
| TWST | Twist Bioscience Corp | $5.03B | $80.79 | — |
| IMVT | Immunovant, Inc. | $6.87B | $33.44 | — |
News headlines (Yahoo Finance, 1h cache)
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding
2026-06-11 02:04 · Yahoo
Apogee (APGE) Secures Up to $1.3B in Non-Dilutive Financing from Blackstone to Advance Zumilokibart
2026-06-05 12:55 · Yahoo
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing
2026-06-04 09:04 · Yahoo
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart
2026-06-01 05:04 · Yahoo
Apogee Therapeutics to Participate in Upcoming June Conferences
2026-05-28 20:01 · Yahoo
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program
2026-05-28 18:43 · Yahoo
Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results
2026-05-27 20:05 · Yahoo
Blackstone Backs Apogee With Up To $1.3 Billion
2026-05-27 18:33 · Yahoo
Apogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG)
2026-05-27 12:06 · Yahoo
Apogee Therapeutics, Blackstone Life Sciences Enter Financing Collaboration of Up to $1.3 Billion
2026-05-27 11:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.